Biotech Archives - Page 6 of 733

1 minute read

Ultragenyx Plans To File For Accelerated Approval Of UX111 For The Treatment Of Sanfilippo Syndrome Type A, After Meeting With FDA

June 12, 4:00 PM

Agreement reached with FDA that cerebral spinal fluid (CSF) heparan sulfate (HS) can be used as a reasonable surrogate endpoint for accelerated approval Data from existing clinical studies appear sufficient for a

RARE

5 minute read

‘Oregon’s First-In-Nation Psilocybin Industry Is Struggling To Find Paying Customers A Year After Launching’ – Marijuana Moment

By Benzinga Newsdesk

June 12, 2:07 PM

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after-launching/"Unfortunately we've seen one service center close down. I imagine there will be

CMPS

1 minute read

Jaguar Health To Present Phase 3 OnTarget Trial Results For Its Cancer Supportive Care Drug Crofelemer On Or Before July 23, 2024

By Benzinga Newsdesk

June 12, 8:38 AM

Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer

JAGX

1 minute read

IceCure Medical Reports Data From Its Kidney Cancer Clinical Study Presented At Interventional Radiology Conference Dsud Minimally Invasive Approach Results In Shorter Hospitalization And Minor Impact On Renal Function

By Benzinga Newsdesk

June 12, 8:32 AM

ICESECRET interim results, as previously announced, demonstrated ProSense® to be safe and effective in treating kidney tumors with 89.5% recurrence-free rateMore data is expected in the fourth quarter of 2024,

ICCM

1 minute read

bioAffinity Technologies Sees Accelerating Growth Of Physician Practices Ordering CyPath Lung Tests

By Benzinga Newsdesk

June 12, 8:11 AM

Sales of CyPath® Lung tests, onboarding of pathology practices ahead of forecastsbioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW))), a biotechnology company focused on the need for noninvasive tests for the

BIAF

2 minute read

Reported Monday June 10, 2024 “Amneal, U.S. FTC Win Order Removing Teva Inhaler Patents From FDA List” – Reuters News

By Benzinga Newsdesk

June 11, 10:40 AM

https://www.reuters.com/legal/litigation/amneal-us-ftc-win-order-removing-teva-inhaler-patents-fda-list-2024-06-10/ Drugmaker Amneal Pharmaceuticals (AMRX.O), opens new tab with the backing of the U.S. Federal Trade

AMRX

1 minute read

Charles River Laboratories In Collaboration With MatTek Awarded $1.3M Grant From The Foundation For Chemistry Research And Initiatives To Advance Research Alternatives

By Benzinga Newsdesk

June 11, 8:19 AM

Project will utilize an integrated approach to develop an in vitro alternative to inhalation toxicology studiesCharles River Laboratories International, Inc. (NYSE:CRL) today announced a multidisciplinary program, funded

CRL

1 minute read

Annovis Bio’s Recent Phase II/III Alzheimer’s Study Of Buntanetap, Showed Statistically Significant Efficacy And Safety In Both Carriers And Non-Carriers Of Apolipoprotein E4, A Genetic Cause Of AD

By Benzinga Newsdesk

June 11, 8:08 AM

Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), today

ANVS

1 minute read

Biora Therapeutics To Present On The BioJet Systemic Oral Delivery Platform At The Next Gen Peptide Formulation & Delivery Summit 2024

By Benzinga Newsdesk

June 11, 8:06 AM

Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the

BIOR

1 minute read

Arcutis Presents New Long-Term Data Of Roflumilast Cream 0.15% For The Treatment Of Mild To Moderate Atopic Dermatitis In Adults And Children Down To Age 6 At The Revolutionizing Alopecia Areata, Vitiligo, And Eczema Conference

By Benzinga Newsdesk

June 10, 2:32 PM

Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment 66.2% of participants treated with once-daily roflumilast cream

ARQT